SCHEDULE 13G: Paradigm BioCapital Group Discloses 5% Passive Stake in Edgewise Therapeutics

A group of investment entities and individuals associated with Paradigm BioCapital have disclosed a passive beneficial ownership of 5.0% in Edgewise Therapeutics, Inc. common stock.

Summary

• A group of reporting persons, including Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D., have disclosed a collective beneficial ownership of 4,738,929 shares of Edgewise Therapeutics, Inc. common stock, representing 5.0% of the class.
• Paradigm BioCapital International Fund Ltd., a private investment vehicle managed by Paradigm BioCapital Advisors LP, directly beneficially owns 4,181,497 shares, or 4.4% of the class, and is included in the aggregate beneficial ownership of the other reporting persons.
• The filing is a Schedule 13G, indicating a passive investment without the intent to influence or change control of the issuer, filed under Rule 13d-1(c).
• The event date triggering this filing was January 27, 2025.
• The percentage of beneficial ownership is calculated based on 94,688,517 shares of Common Stock outstanding as of October 31, 2024, as reported by the Issuer in its Form 10-Q filed on November 7, 2024.

Sentiment

Score: 7

Explanation: The disclosure of a new significant passive investor is generally a positive signal, indicating institutional interest and potential validation of the company's value proposition, even if the investor is not seeking control.

Positives

• Significant institutional investment: Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. have collectively acquired a 5.0% passive stake in Edgewise Therapeutics, indicating a notable investment interest.
• Increased investor confidence: The acquisition of a 5% stake by a specialized investment group may signal confidence in Edgewise Therapeutics' future prospects and valuation.

Negatives

• No active engagement: The filing indicates a passive investment, meaning the reporting persons do not intend to influence or change control of Edgewise Therapeutics, which limits potential for activist-driven value creation.

Risks

• The investment is passive, meaning the reporting persons do not intend to influence or change control of the issuer, which limits potential for activist-driven value creation or strategic shifts driven by this shareholder.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance from Edgewise Therapeutics, Inc. or the reporting persons regarding the issuer's future performance or strategic direction.

Management Comments

• The filing is a disclosure of beneficial ownership by investment entities and does not contain direct management comments from Edgewise Therapeutics, Inc. The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

The disclosure of a significant passive stake by an investment group like Paradigm BioCapital is a common occurrence in the public markets, reflecting institutional interest in companies. While this filing does not provide specific industry trends, it indicates that Edgewise Therapeutics, Inc. has attracted attention from specialized investment funds.

Comparison to Industry Standards

• This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information for comparison to industry standards, specific comparable companies, projects, or results.

Stakeholder Impact

• Shareholders: May view the new significant institutional investor as a positive sign, potentially increasing confidence in the stock and its long-term prospects.
• Management: Awareness of a new large passive shareholder, but no direct impact on operations or strategy is implied by a Schedule 13G filing.

Next Steps

• The filing itself does not outline specific future actions or milestones for Edgewise Therapeutics, Inc. or the reporting persons, beyond the ongoing passive investment.

Key Dates

Recommendation

Keywords

Edgewise Therapeutics, Schedule 13G, Passive Investment, Institutional Ownership, SEC Filing, Paradigm BioCapital, Common Stock, Beneficial Ownership, Biotechnology